Literature DB >> 23901090

Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.

Monique van Velzen1, David A M C van de Vijver, Freek B van Loenen, Albert D M E Osterhaus, Lies Remeijer, Georges M G M Verjans.   

Abstract

PURPOSE: Long-term acyclovir (ACV) prophylaxis, recommended to prevent recurrent herpes simplex virus type 1 (HSV-1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance. We determined the effect of ACV prophylaxis on the prevalence of corneal ACV-resistant (ACV(R)) HSV-1 and clinical consequences thereof in patients with recurrent HSV-1 keratitis (rHK).
METHODS: Frequencies of ACV(R) viruses were determined in 169 corneal HSV-1 isolates from 78 rHK patients with a history of stromal disease. The isolates' ACV susceptibility profiles were correlated with clinical parameters to identify risk factors predisposing to ACV(R) rHK.
RESULTS: Corneal HSV-1 isolates with >28% ACV(R) viruses were defined as ACV(R) isolates. Forty-four isolates (26%) were ACV-resistant. Multivariate analyses identified long-term ACV prophylaxis (≥12 months) (odds ratio [OR] 3.42; 95% confidence interval [CI], 1.32-8.87) and recurrence duration of ≥45 days (OR 2.23; 95% CI, 1.02-4.87), indicative of ACV-refractory disease, as independent risk factors for ACV(R) isolates. Moreover, a corneal ACV(R) isolate was a risk factor for ACV-refractory disease (OR 2.28; 95% CI, 1.06-4.89).
CONCLUSIONS: The data suggest that long-term ACV prophylaxis predisposes to ACV-refractory disease due to the emergence of corneal ACV(R) HSV-1. ACV-susceptibility testing is warranted during follow-up of rHK patients.

Entities:  

Keywords:  acyclovir prophylaxis; acyclovir resistance; patients; recurrent keratitis; refractory disease; retrospective study; risk factors

Mesh:

Substances:

Year:  2013        PMID: 23901090     DOI: 10.1093/infdis/jit350

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication.

Authors:  John E Tavis; Hong Wang; Ann E Tollefson; Baoling Ying; Maria Korom; Xiaohong Cheng; Feng Cao; Katie L Davis; William S M Wold; Lynda A Morrison
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 3.  Update on Herpes simplex keratitis management.

Authors:  Daniel Sibley; Daniel F P Larkin
Journal:  Eye (Lond)       Date:  2020-08-25       Impact factor: 3.775

4.  Synthetic α-Hydroxytropolones Inhibit Replication of Wild-Type and Acyclovir-Resistant Herpes Simplex Viruses.

Authors:  Peter J Ireland; John E Tavis; Michael P D'Erasmo; Danielle R Hirsch; Ryan P Murelli; Mark M Cadiz; Bindi S Patel; Ankit K Gupta; Tiffany C Edwards; Maria Korom; Eileen A Moran; Lynda A Morrison
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 5.  Application of our understanding of pathogenesis of herpetic stromal keratitis for novel therapy.

Authors:  Naveen K Rajasagi; Barry T Rouse
Journal:  Microbes Infect       Date:  2018-01-09       Impact factor: 2.700

Review 6.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea.

Authors:  Lulia Koujah; Rahul K Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

7.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

8.  Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.

Authors:  James M Hill; Debra C Quenelle; Rhonda D Cardin; Jodi L Vogel; Christian Clement; Fernando J Bravo; Timothy P Foster; Marta Bosch-Marce; Priya Raja; Jennifer S Lee; David I Bernstein; Philip R Krause; David M Knipe; Thomas M Kristie
Journal:  Sci Transl Med       Date:  2014-12-03       Impact factor: 17.956

9.  Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Authors:  Natacha Coen; Sophie Duraffour; Kazuhiro Haraguchi; Jan Balzarini; Joost J van den Oord; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

10.  Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors.

Authors:  Takashi Masaoka; Haiyan Zhao; Danielle R Hirsch; Michael P D'Erasmo; Christine Meck; Brittany Varnado; Ankit Gupta; Marvin J Meyers; Joel Baines; John A Beutler; Ryan P Murelli; Liang Tang; Stuart F J Le Grice
Journal:  Biochemistry       Date:  2016-02-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.